In this article, we will be taking a look at the 12 best healthcare stocks to buy under $30.

Mizuho health care sector strategist Jared Holz made an appearance on CNBC’s “The Exchange” on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities in the field.

He said that it would be wonderful to occasionally cover a sector that outperforms the market, and said that he is undoubtedly upset with the current dynamics in the healthcare industry.

According to the strategist, the only times the healthcare industry has outperformed the market over the last ten years, and even then, that wasn’t a good setup, are when the market was down. Holz believes that the performance of the large-cap pharmaceutical business is significantly impacted by a cascade of problems.

He added to CNBC that nothing even comes close to this kind of pressure across the board if we go back a few decades, making this the worst the healthcare industry has ever experienced. Holz identified managed care and pharmaceuticals as the main offenders, claiming that they are bearing the most burden in terms of market capitalization.

With these trends in view, let’s look at the 12 Best Healthcare Stocks to Buy Under $30.

Our Methodology 

For our methodology, we screened stocks with a share price below $30 and ranked them according to the number of hedge fund holders as of Q1 2025, based on data from the Insider Monkey database. Additionally, we included the share price as of the most recent closing (11 August) in the subheadings for clarity.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 12 best healthcare stocks to buy under $30.  

12. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 10 

Share Price: $2.47 

ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells.

A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk.

In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion.

ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA’s expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders.

11. Cronos Group Inc. (NASDAQ:CRON)

Number of Hedge Fund Holders: 13 

Share Price: $2.67 

Cronos Group Inc. (NASDAQ:CRON) is a global cannabis company operating primarily in Canada and Israel, with recognized brands like PEACE NATURALS and Spinach. The company focuses on both medicinal and recreational cannabis markets and is expanding internationally into Australia, Malta, Germany, and Switzerland.

In Q2 2025, Cronos Group Inc. (NASDAQ:CRON) reported a 21% year-over-year revenue increase to $33.5 million, driven mainly by its PEACE NATURALS brand in Israel and other international markets. Despite a net loss of $38.5 million influenced partly by foreign exchange impacts, the consolidation of its Canadian cultivation subsidiary, Cronos GrowCo, contributed $2.2 million in flower sales and helped boost gross margins from 23% to 43%.

The business strategically focuses on global markets like Israel to offset U.S. regulatory uncertainties and recently resolved an anti-dumping dispute there, stabilizing its international operations. The corporation maintains a strong liquidity position with $834 million in cash and short-term investments, supporting initiatives like an $18.5 million convertible loan investment in Canadian retailer High Tide Inc.

Looking ahead, analysts expect profitability to improve with a 50% capacity increase at GrowCo, supporting rising demand and better margins. Q3 2025 revenue is forecasted at $37.3 million with adjusted EBITDA rising to $5.6 million, reflecting operational momentum. Additionally, Cronos Group Inc. (NASDAQ:CRON) announced a $50 million share repurchase program, signaling confidence in its growth prospects.

10. Tilray Brands, Inc. (NASDAQ:TLRY)

Number of Hedge Fund Holders: 14 

Share Price: $0.92 

Tilray Brands, Inc. (NASDAQ:TLRY) is a global lifestyle and consumer goods company focused on cannabis, beverages, and wellness. In June 2025, the company launched its 2025 summer cannabis collection in Canada, featuring new THC beverages, pre-rolls, vapes, aromatic flowers, and infused edibles. This product diversification targets varied consumer preferences and reinforces Tilray’s leadership in the cannabis market.

Recently, Tilray Brands, Inc. (NASDAQ:TLRY) expanded into wellness snacks with the launch of Humble Seed Whole Wheat Protein Crackers at Whole Foods Market, marking a strategic move beyond cannabis. This launch triggered a 4.9% share price increase, an analyst upgrade, and a significant insider purchase by CEO Irwin D. Simon, reflecting strong confidence in the company’s growth direction. While not traditionally in the same category, some investors view Tilray’s wellness and pharmaceutical distribution segment as aligning with certain best healthcare stocks themes due to its role in health-oriented consumer products

the business’s diversified revenue streams now include cannabis (30%), beverages (29%), pharmaceutical and wellness product distribution (33%), and hemp-based foods (8%). This broad portfolio helps mitigate regulatory risks in the U.S. and supports long-term growth. Tilray Brands, Inc. (NASDAQ:TLRY) projects adjusted EBITDA growth of 13–31% for the fiscal year ending May 2026, which indicates optimism about expanding operations and profitability.

9. Neogen Corporation (NASDAQ:NEOG)

Number of Hedge Fund Holders: 15 

Share Price: $5.11 

Neogen Corporation (NASDAQ:NEOG), specializing in food and animal safety diagnostics, is currently undergoing a strategic transition amid operational challenges. As of August 2025, the company faced integration issues from past mergers and reported weaker Q3 2025 earnings, leading to lowered full-year guidance and an announced CEO departure later this year.

Despite these setbacks, Neogen Corporation (NASDAQ:NEOG) is divesting non-core operations to reduce debt and improve future growth prospects. Investors like Baron Funds view this restructuring as a temporary phase before a stronger rebound. The business operates mainly in Food Safety and Animal Safety, providing diagnostic kits for contaminants and veterinary products, reinforcing its role in global food and animal health.

A notable recent development is Neogen Corporation (NASDAQ:NEOG)’s August 2025 collaboration with enzyme design firm Biomatter, signaling a strategic move toward biotechnological innovation. Additionally, the company’s Q2 CY2025 results beat revenue expectations despite a 4.8% year-over-year sales decline, demonstrating some resilience in a difficult market environment.

8. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Holders: 17 

Share Price: $4.5 

AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotech company specializing in discovering and developing therapeutic antibodies across various disease areas, including cancer, metabolic, endocrine, and autoimmune disorders. Their integrated platform combines technology, data science, and collaboration to identify promising antibody candidates.

In recent developments, AbCellera Biologics Inc. (NASDAQ:ABCL) began dosing participants in a Phase 1 clinical trial for ABCL635, targeting vasomotor symptoms related to menopause, marking a key clinical milestone. The company reported strong Q2 2025 revenue growth, beating expectations and advancing both internal and partnered antibody programs despite ongoing net losses. Some analysts note that its innovative pipeline and expanding clinical presence could place it among the best healthcare stocks to watch in the biotech space.

This Phase 1 trial signals the corporation’s shift from primarily a discovery platform to a clinical-stage biotech with proprietary assets. Progress with ABCL635 addresses a significant unmet medical need and validates its platform’s potential to develop first-in-class therapeutics.

7. Medical Properties Trust, Inc. (NYSE:MPW)

Number of Hedge Fund Holders: 19 

Share Price: $4.03 

Medical Properties Trust, Inc. (NYSE:MPW) is a REIT specializing in acquiring and developing net-leased hospital and healthcare properties. It leases or loans these assets to hospital operators, enabling them to unlock real estate value and reinvest in facility improvements.

As of August 2025, Medical Properties Trust, Inc. (NYSE:MPW) filed a prospectus for an at-the-market equity program to raise $500 million, aimed at debt repayment and healthcare property acquisitions. By mid-2025, its portfolio included 392 properties across acute care hospitals, behavioral health, post-acute facilities, and freestanding ER centers, leased or loaned to 53 tenants. Approximately 4% of the portfolio is either in development or unleased, with no single property exceeding 2% of total assets.

Following challenges such as tenant bankruptcies, the business has focused on stabilizing operations by improving rent collections and transitioning properties to new operators. Its Q2 2025 results showed sequential improvement, with revenues and normalized funds from operations surpassing expectations, which signals a potential turnaround despite ongoing risks from leverage, interest costs, and tenant uncertainties.

Looking ahead, Medical Properties Trust, Inc. (NYSE:MPW) plans to continue its acquisition strategy, leveraging the equity raise to strengthen its balance sheet and further stabilize its tenant base.

6. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 19 

Share Price: $5.29 

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development.

In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech.

The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities.

Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s oncology pipeline has broadened, with several candidates expected to advance into human studies.

5. LifeStance Health Group, Inc. (NASDAQ:LFST)

Number of Hedge Fund Holders: 24 

Share Price: $4.57 

LifeStance Health Group, Inc. (NASDAQ:LFST) stands fifth among the best healthcare stocks. It is one of the largest outpatient mental health providers in the U.S. that operates over 550 locations across 33 states with nearly 7,500 clinicians, offering a hybrid of in-person and telehealth care (about 70% virtual). The company primarily serves patients with commercial insurance and focuses on expanding access to affordable behavioral health services.

In 2025, LifeStance Health Group, Inc. (NASDAQ:LFST) accelerated its digital transformation, with a strong emphasis on artificial intelligence (AI) to improve efficiency. AI tools are being deployed in revenue cycle management, patient scheduling, and soon, clinician documentation, aimed at reducing administrative burdens and improving satisfaction. The appointment of Vaughn Paunovich as CTO marks a renewed push toward technology-driven operations.

As part of this effort, the business is reviewing new electronic health record (EHR) platforms, with a decision expected by late 2025. Operational upgrades also include a digital patient check-in tool, improved HR and credentialing systems, and enhanced payer engagement platforms. These changes are designed to strengthen operational foundations for sustainable growth rather than rapid, acquisition-heavy expansion.

Q2 2025 saw an 11% increase in clinicians (173 added), supported by scheduling and productivity technologies that have improved retention and patient management.

LifeStance Health Group, Inc. (NASDAQ:LFST) expects these digital and AI investments to yield significant productivity gains and improved patient care from 2026 onward, positioning the company as a leader in next-generation, tech-enabled mental health services.

4. OPKO Health, Inc. (NASDAQ:OPK)

Number of Hedge Fund Holders: 26 

Share Price: $1.30 

OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations in diagnostics, pharmaceuticals, and innovative therapies, anchored by BioReference Laboratories and an expanding drug development pipeline. The company is advancing programs in immunology, endocrinology, oncology, and metabolic disorders through both internal research and strategic collaborations.

In 2025, OPKO Health, Inc. (NASDAQ:OPK) made notable progress across multiple fronts. In partnership with Merck, it is advancing a Phase 1 trial for an experimental Epstein-Barr virus (EBV) vaccine, which could move to Phase 2 pending trial results. Its metabolic disease pipeline includes OPK-88006, an investigational oral GLP-1/glucagon dual agonist for obesity and metabolic-associated steatohepatitis (MASH). Data presented at ENDO 2025 demonstrated strong bioavailability and efficacy, with both oral and weekly injectable formats in development.

The company is also working with Entera Bio on an oral GLP-2 agonist for short bowel syndrome, with promising PK/PD data set for presentation at the 2025 ESPEN Congress. In oncology, the business’s subsidiary ModeX is developing multispecific antibody therapeutics, with four clinical candidates, including lymphoma and leukemia treatments, targeting a range of solid tumors and blood cancers, and human trials expected to begin in early 2026.

On the diagnostics front, the FDA approved a key update to OPKO’s 4KScore Test, allowing use without digital rectal examination data, broadening its role in primary care for prostate cancer risk assessment. Additionally, the planned sale of certain BioReference oncology and clinical testing assets to Labcorp, expected to close in late 2025, will allow OPKO Health, Inc. (NASDAQ:OPK) to sharpen its focus on core diagnostics and pharmaceuticals while improving operational efficiency.

3. MannKind Corporation (NASDAQ:MNKD)

Number of Hedge Fund Holders: 29 

Share Price: $3.42 

MannKind Corporation (NASDAQ:MNKD)’s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza’s efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks.

Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025.

To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets.

2. GoodRx Holdings, Inc. (NASDAQ:GDRX)

Number of Hedge Fund Holders: 30 

Share Price: $3.48 

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading U.S. digital healthcare platform that helps consumers compare prescription drug prices and access discounts, while also expanding into telehealth and other healthcare services.

A major recent focus is the company’s growth in pharma manufacturer solutions, where it partners with drug makers for targeted advertising and patient access programs. In Q2 2025, revenue from this segment rose 32%, prompting GoodRx to raise its full-year growth forecast from 20% to 30%. This shift diversifies its business beyond traditional prescription savings cards and strengthens its role as a key marketing partner for pharmaceutical companies.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is also broadening its consumer offerings through subscription-based services, including a new program for affordable erectile dysfunction medications (Sildenafil and Tadalafil). These initiatives support its mission of lowering out-of-pocket drug costs while enhancing direct-to-consumer healthcare access. Its telehealth platform remains an important but underutilized growth channel, with potential for further expansion. Additionally, GoodRx Holdings, Inc. (NASDAQ:GDRX) is undergoing a brand relaunch and implementing targeted marketing strategies to boost engagement and market share.

1. Clover Health Investments, Corp. (NASDAQ:CLOV)

Number of Hedge Fund Holders: 33 

Share Price: $2.47 

Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the best healthcare stocks. It is a Medicare Advantage insurer that leverages its AI-powered Clover Assistant platform to improve health outcomes, particularly for chronic conditions such as congestive heart failure. Its PPO-focused model offers broader network access compared to typical HMO plans, aiming to reduce hospitalizations and readmissions through advanced analytics and clinical decision support.

In Q2 2025, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members. Insurance revenue grew 34% to about $470 million, with adjusted EBITDA and net income both at roughly $17 million, maintaining profitability despite elevated sector-wide medical costs.

Clover Assistant has demonstrated measurable impact, including an 18% reduction in hospitalizations and 25% fewer 30-day readmissions for heart failure patients under its care model. The business plans to use these results as a competitive differentiator and is expanding the platform to other risk-bearing organizations.

The corporation also improved its Medicare star ratings, with PPO plans projected to rise from 3.5 stars in 2025 to 4.0 stars in 2026, boosting reimbursement potential and market competitiveness. While facing rising costs from supplemental benefits and regulatory changes, Clover Health Investments, Corp. (NASDAQ:CLOV) is pursuing cost-efficiency measures such as renegotiating partnerships and expects these efforts, along with regulatory adjustments, to help ease pressures by 2026.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.